The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
about
Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantationSecond hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation.Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantationAntilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects.Management of acute graft-versus-host disease.Prevention and treatment of acute GvHD.Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remissionAcute graft-versus-host disease: new treatment strategies.Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.Bone marrow transplantation for beta-thalassaemia major by an HLA-mismatched parent.Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis.A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease.Naso-jejunal feeding in allogeneic bone marrow transplant recipients: results of a pilot study.Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing.Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease.
P2860
Q34134601-36713792-0DB8-4E31-882B-9438E48C8004Q34616704-A5D8D2E7-6679-4878-BE24-B4D691C74989Q35574785-45B8AEB0-1BC2-4FE6-AF00-2A4A3FAAB2DDQ35959473-8216FDBB-5C7C-4535-BD2B-B7765A9C6DDAQ36773002-41472CC5-AB5B-4C09-9217-A95ABB3F60AAQ37188487-DE70C48E-895A-4CF2-87D2-56570DA7679FQ37369934-4657E6D3-2D8B-4F31-8D97-07D2231B4B14Q37610714-7CB6FA3C-9684-4F1F-9070-0529D7F4851BQ37635642-91384D47-0B32-4CF9-899F-087747263D0AQ43690748-913D7CFA-6942-4BE3-BC16-E0F4D0579F08Q44016550-DA76BE4E-0656-4956-B576-030138C49632Q44208132-5A9B6F29-3E25-4130-9DDE-89CE0D92A2DFQ44780698-1FFBEC7E-DC62-4613-8E4A-0C092E4BE87CQ48651160-1F8B5ACF-34FE-4D17-9CB4-56032DA33AFBQ49332656-638559EB-864B-49E8-8492-F0FBE722FB7BQ50967594-4728E6AE-7E9F-4AF9-A1F7-20FE0AD43CAFQ51000653-66A3D572-8DFA-4A16-B829-E7DF831C3149Q51729292-FC345001-A3F4-4D90-9AE8-D821FB648B6BQ54308886-5CBBCDFD-ABFC-4374-A7D6-9A2E679EB14D
P2860
The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
The effect of the serotherapy ...... transplantation for leukaemia.
@en
The effect of the serotherapy ...... transplantation for leukaemia.
@nl
type
label
The effect of the serotherapy ...... transplantation for leukaemia.
@en
The effect of the serotherapy ...... transplantation for leukaemia.
@nl
prefLabel
The effect of the serotherapy ...... transplantation for leukaemia.
@en
The effect of the serotherapy ...... transplantation for leukaemia.
@nl
P2093
P2860
P356
P1476
The effect of the serotherapy ...... transplantation for leukaemia
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BMT.1702165
P407
P577
2000-02-01T00:00:00Z
P5875
P6179
1015445815